{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T18:05:50Z","timestamp":1794593150045,"version":"4.9.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.urolonc.2009.03.029","type":"journal-article","created":{"date-parts":[[2009,12,30]],"date-time":"2009-12-30T04:23:10Z","timestamp":1262146990000},"page":"108-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG"],"prefix":"10.1016","volume":"28","author":[{"given":"LaMont J.","family":"Barlow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Seager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell C.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2009.03.029_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib2","series-title":"Campbell-Walsh Urology, 9th ed. Vol. III","article-title":"Non-muscle-invasive bladder cancer (Ta, T1, and CIS)","author":"Jones","year":"2006"},{"key":"10.1016\/j.urolonc.2009.03.029_bib3","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0022-5347(01)65673-8","article-title":"A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only vs","volume":"156","author":"Krege","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-5347(17)49690-X","article-title":"Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer","volume":"132","author":"Morales","year":"1984","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib5","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0022-5347(17)43959-0","article-title":"Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer","volume":"137","author":"Catalona","year":"1987","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib6","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2007.06912.x","article-title":"The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy","volume":"100","author":"Lambert","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2009.03.029_bib8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1078-1439(03)00144-3","article-title":"Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy","volume":"2","author":"Bianco","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib9","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1200\/JCO.2005.03.1161","article-title":"Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy","volume":"24","author":"McKiernan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib10","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s00345-002-0275-2","article-title":"New drugs and new approaches for the treatment of metastatic urothelial cancer","volume":"20","author":"Calabro","year":"2002","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib11","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s002800050660","article-title":"Bladder tissue pharmacokinetics of intravesical taxol","volume":"40","author":"Song","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib12","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib13","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.1997.15.12.3441","article-title":"Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer","volume":"15","author":"Moore","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib14","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib15","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib16","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2009.03.029_bib17","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.cgt.7700488","article-title":"Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer","volume":"9","author":"Yamashita","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.urolonc.2009.03.029_bib19","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1158\/0008-5472.CAN-08-0234","article-title":"Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer","volume":"68","author":"O'Brien","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2009.03.029_bib20","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z","article-title":"Molecular analysis of PTEN and MXI1 in primary bladder carcinoma","volume":"88","author":"Wang","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2009.03.029_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.pathol.4.110807.092230","article-title":"Molecular pathogenesis and diagnostics of bladder cancer","volume":"4","author":"Mitra","year":"2009","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.urolonc.2009.03.029_bib22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1101\/gad.1772909","article-title":"Inactivation of p53 and Pten Promotes Invasive Bladder Cancer","volume":"23","author":"Puzio-Kuter","year":"2009","journal-title":"Genes and Development"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143909001045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143909001045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:26:16Z","timestamp":1790249176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143909001045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S1078143909001045"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2009.03.029","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2009.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}